Results: This study enrolled 1,343 treatment-naïve patients with EGFR-mutated advanced NSCLC, of whom 554 were aged <65 years, 383 were aged 65–74 years, 323 were aged 75–84 years, and 83 were aged ≥85 years. This evidence concerns the gene EGFR and non-small cell lung carcinoma.